FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071729803> ?p ?o ?g. }

• W2071729803 endingPage "78" @default.
• W2071729803 startingPage "71" @default.
• W2071729803 abstract "PurposeRadiation Therapy Oncology Group (RTOG) 0118 randomized patients with multiple brain metastases to whole-brain radiotherapy (WBRT) ± thalidomide. This secondary analysis of 156 patients examined neurocognitive and quality of life (QOL) outcomes.Methods and MaterialsQuality of life was determined with the Spitzer Quality of Life Index (SQLI). The Folstein Mini-Mental Status Exam (MMSE) assessed neurocognitive function. SQLI and MMSE were administered at baseline and at 2-month intervals. MMSE was scored with a threshold value associated with neurocognitive functioning (absolute cutoff level of 23) and with the use of corrections for age and educational level.ResultsBaseline SQLI predicted survival. Patients with SQLI of 7–10 vs. <7 had median survival time (MST) of 4.8 vs. 3.1 months, p = 0.05. Both arms showed steady neurocognitive declines, but SQLI scores remained stable. Higher levels of neurocognitive decline were observed with age and education-level corrections. Of patients considered baseline age/educational level neurocognitive failures, 32% died of intracranial progression.ConclusionsQuality of life and neuropsychological testing can be prospectively administered on a Phase III cooperative group trial. The MMSE should be evaluated with adjustments for age and educational level. Baseline SQLI is predictive of survival. Despite neurocognitive declines, QOL remained stable during treatment and follow-up. Poor neurocognitive function may predict clinical deterioration. Lack of an untreated control arm makes it difficult to determine the contribution of the respective interventions (i.e., WBRT, thalidomide) to neurocognitive decline. The RTOG has developed a trial to study the role of preventative strategies aimed at forestalling neurocognitive decline in this population. Radiation Therapy Oncology Group (RTOG) 0118 randomized patients with multiple brain metastases to whole-brain radiotherapy (WBRT) ± thalidomide. This secondary analysis of 156 patients examined neurocognitive and quality of life (QOL) outcomes. Quality of life was determined with the Spitzer Quality of Life Index (SQLI). The Folstein Mini-Mental Status Exam (MMSE) assessed neurocognitive function. SQLI and MMSE were administered at baseline and at 2-month intervals. MMSE was scored with a threshold value associated with neurocognitive functioning (absolute cutoff level of 23) and with the use of corrections for age and educational level. Baseline SQLI predicted survival. Patients with SQLI of 7–10 vs. <7 had median survival time (MST) of 4.8 vs. 3.1 months, p = 0.05. Both arms showed steady neurocognitive declines, but SQLI scores remained stable. Higher levels of neurocognitive decline were observed with age and education-level corrections. Of patients considered baseline age/educational level neurocognitive failures, 32% died of intracranial progression. Quality of life and neuropsychological testing can be prospectively administered on a Phase III cooperative group trial. The MMSE should be evaluated with adjustments for age and educational level. Baseline SQLI is predictive of survival. Despite neurocognitive declines, QOL remained stable during treatment and follow-up. Poor neurocognitive function may predict clinical deterioration. Lack of an untreated control arm makes it difficult to determine the contribution of the respective interventions (i.e., WBRT, thalidomide) to neurocognitive decline. The RTOG has developed a trial to study the role of preventative strategies aimed at forestalling neurocognitive decline in this population." @default.
• W2071729803 created "2016-06-24" @default.
• W2071729803 creator A5003825991 @default.
• W2071729803 creator A5004625690 @default.
• W2071729803 creator A5018381770 @default.
• W2071729803 creator A5026088869 @default.
• W2071729803 creator A5027150108 @default.
• W2071729803 creator A5039395742 @default.
• W2071729803 creator A5046338327 @default.
• W2071729803 creator A5046534928 @default.
• W2071729803 creator A5065815535 @default.
• W2071729803 creator A5070189726 @default.
• W2071729803 creator A5080119679 @default.
• W2071729803 creator A5089928649 @default.
• W2071729803 date "2008-05-01" @default.
• W2071729803 modified "2023-10-16" @default.
• W2071729803 title "Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118" @default.
• W2071729803 cites W1510465714 @default.
• W2071729803 cites W1881225095 @default.
• W2071729803 cites W1940514332 @default.
• W2071729803 cites W1967332503 @default.
• W2071729803 cites W1985500863 @default.
• W2071729803 cites W2001739398 @default.
• W2071729803 cites W2008153607 @default.
• W2071729803 cites W2026787549 @default.
• W2071729803 cites W2032254273 @default.
• W2071729803 cites W2045688297 @default.
• W2071729803 cites W2047930883 @default.
• W2071729803 cites W2049116727 @default.
• W2071729803 cites W2058740898 @default.
• W2071729803 cites W2075184473 @default.
• W2071729803 cites W2080201870 @default.
• W2071729803 cites W2095813725 @default.
• W2071729803 cites W2098794292 @default.
• W2071729803 cites W2104220103 @default.
• W2071729803 cites W2104697046 @default.
• W2071729803 cites W2105932966 @default.
• W2071729803 cites W2113465576 @default.
• W2071729803 cites W2125904639 @default.
• W2071729803 cites W2132173438 @default.
• W2071729803 cites W2146504042 @default.
• W2071729803 cites W2151749637 @default.
• W2071729803 cites W2162416075 @default.
• W2071729803 cites W2168161641 @default.
• W2071729803 cites W2169039112 @default.
• W2071729803 cites W2170736271 @default.
• W2071729803 cites W2170736348 @default.
• W2071729803 cites W2171092076 @default.
• W2071729803 cites W222518019 @default.
• W2071729803 cites W2315731861 @default.
• W2071729803 cites W4293241248 @default.
• W2071729803 doi "https://doi.org/10.1016/j.ijrobp.2007.09.015" @default.
• W2071729803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18164829" @default.
• W2071729803 hasPublicationYear "2008" @default.
• W2071729803 type Work @default.
• W2071729803 sameAs 2071729803 @default.
• W2071729803 citedByCount "46" @default.
• W2071729803 countsByYear W20717298032012 @default.
• W2071729803 countsByYear W20717298032013 @default.
• W2071729803 countsByYear W20717298032014 @default.
• W2071729803 countsByYear W20717298032015 @default.
• W2071729803 countsByYear W20717298032016 @default.
• W2071729803 countsByYear W20717298032017 @default.
• W2071729803 countsByYear W20717298032018 @default.
• W2071729803 countsByYear W20717298032019 @default.
• W2071729803 countsByYear W20717298032020 @default.
• W2071729803 countsByYear W20717298032022 @default.
• W2071729803 crossrefType "journal-article" @default.
• W2071729803 hasAuthorship W2071729803A5003825991 @default.
• W2071729803 hasAuthorship W2071729803A5004625690 @default.
• W2071729803 hasAuthorship W2071729803A5018381770 @default.
• W2071729803 hasAuthorship W2071729803A5026088869 @default.
• W2071729803 hasAuthorship W2071729803A5027150108 @default.
• W2071729803 hasAuthorship W2071729803A5039395742 @default.
• W2071729803 hasAuthorship W2071729803A5046338327 @default.
• W2071729803 hasAuthorship W2071729803A5046534928 @default.
• W2071729803 hasAuthorship W2071729803A5065815535 @default.
• W2071729803 hasAuthorship W2071729803A5070189726 @default.
• W2071729803 hasAuthorship W2071729803A5080119679 @default.
• W2071729803 hasAuthorship W2071729803A5089928649 @default.
• W2071729803 hasConcept C118552586 @default.
• W2071729803 hasConcept C126322002 @default.
• W2071729803 hasConcept C14216870 @default.
• W2071729803 hasConcept C143998085 @default.
• W2071729803 hasConcept C159110408 @default.
• W2071729803 hasConcept C168563851 @default.
• W2071729803 hasConcept C169900460 @default.
• W2071729803 hasConcept C172467417 @default.
• W2071729803 hasConcept C2779951463 @default.
• W2071729803 hasConcept C509974204 @default.
• W2071729803 hasConcept C71924100 @default.
• W2071729803 hasConceptScore W2071729803C118552586 @default.
• W2071729803 hasConceptScore W2071729803C126322002 @default.
• W2071729803 hasConceptScore W2071729803C14216870 @default.
• W2071729803 hasConceptScore W2071729803C143998085 @default.
• W2071729803 hasConceptScore W2071729803C159110408 @default.
• W2071729803 hasConceptScore W2071729803C168563851 @default.
• W2071729803 hasConceptScore W2071729803C169900460 @default.

• next